ADA and systemic lupus erythematosus: As evidenced in SLE for the use of rituximab [13] and in other immune-mediated diseases for several biopharmaceuticals [14–16], a potential explanation for the lack of efficacy is low drug bioavailability, possibly as a consequence of anti-drug antibody (ADA) formation.